• Unified Protocols for mRNA Lipid Nanoparticle Formulation an

  2026-04-30

  Ma et al. introduce a comprehensive, stepwise protocol for the formulation, characterization, and evaluation of mRNA lipid nanoparticles (LNPs), addressing key technical barriers in the field. Their integrated workflow streamlines mRNA LNP research, providing reproducible guidance for both in vitro and in vivo applications and facilitating broader adoption in mRNA therapeutic development.

• Metabolic Dependencies in IDH1-Mutant Leukemia: AG-120 (Ivos

  2026-04-30

  Explore how AG-120 (Ivosidenib), a selective mutant IDH1 inhibitor, addresses metabolic rewiring in IDH1-mutant leukemia. This article uniquely connects 2-hydroxyglutarate reduction and the CD44 pathway, offering new insights for advanced AML research.

• Fluorinated CXCR4 Inhibitor A1 Outperforms AMD3100 in CRC Mo

  2026-04-29

  Khorramdelazad et al. introduce A1, a novel fluorinated CXCR4 inhibitor, and demonstrate its superior efficacy over AMD3100 in suppressing colorectal cancer progression in preclinical models. Their multidimensional approach highlights the importance of targeting the CXCL12/CXCR4 axis for cancer metastasis inhibition and immune modulation.

• AR Expression Heterogeneity Drives Divergent Prostate Cancer

  2026-04-29

  This study establishes a direct link between androgen receptor (AR) expression heterogeneity in prostate cancer and differential responses to both castration and enzalutamide therapy. By integrating xenograft modeling, genome editing, and transcriptomic analyses, it offers new mechanistic insights and therapeutic strategies for targeting distinct castration-resistant prostate cancer (CRPC) subtypes.

• Redefining mRNA Reporter Workflows: Mechanistic and Strategi

  2026-04-28

  This thought-leadership article explores how EZ Cap™ Firefly Luciferase mRNA with Cap 1 structure empowers translational researchers to overcome persistent barriers in mRNA delivery, gene regulation assays, and in vivo bioluminescence imaging. By blending mechanistic insight with actionable guidance, it positions APExBIO’s product as the new benchmark for quantitative, high-fidelity mRNA workflows. Drawing from recent advances in lipid nanoparticle delivery and expert protocols, the article provides a critical lens on stability, translational efficiency, and application specificity—escalating the discussion beyond traditional product pages and offering a vision for next-generation translational research.

• Proteolytic Neuroligin 1 Fragments Sustain Social Memory in

  2026-04-28

  This study uncovers how social interactions trigger α- and γ-secretase-mediated cleavage of neuroligin 1 in the ventral hippocampus, producing intracellular fragments essential for maintenance of social memory. The findings connect dynamic synaptic remodeling to memory persistence, bridging molecular proteolysis with behavioral outcomes and offering new mechanistic insight relevant to neuropsychiatric disorders.

• ARCA Cy5 EGFP mRNA (5-moUTP): Quantitative mRNA Delivery Ins

  2026-04-27

  ARCA Cy5 EGFP mRNA (5-moUTP) empowers researchers to directly visualize, quantify, and troubleshoot mRNA delivery and translation in mammalian cells. Its 5-methoxyuridine modifications and dual-fluorescent labeling set a new standard for immune-evasive, multiplexed assay workflows.

• Zolmitriptan: Selective 5-HT1B Receptor Agonist for Migraine

  2026-04-27

  Zolmitriptan is a potent, selective 5-HT1B receptor agonist used in migraine and cluster headache research. Its validated mechanism targets serotonin receptor subtypes to induce cranial vasoconstriction and inhibit neuropeptide release. This article provides evidence-backed usage protocols, addresses solubility and stability, and clarifies common misconceptions.

• Clarithromycin as a Gold-Standard CYP3A Inhibitor: Mechanist

  2026-04-26

  This article offers translational researchers an advanced, mechanistically grounded perspective on deploying Clarithromycin as a benchmark CYP3A inhibitor. Integrating evidence from clinical pharmacology, laboratory protocol optimization, and competitive analysis, it provides actionable insights into experimental design, statin metabolism studies, and the future of drug-drug interaction research.

• Applied Use-Cases of JNJ-26481585 (Quisinostat) in Cancer Re

  2026-04-25

  JNJ-26481585 (Quisinostat) is redefining functional epigenetic studies by enabling precise control over tumor suppressor gene activation and drug resistance modulation. This guide distills the latest workflow strategies and troubleshooting insights to maximize reproducibility and biological impact using this advanced HDAC inhibitor.

• Caspase-3 Colorimetric Assay Kit: Technical Application Guid

  2026-04-24

  The Caspase-3 Colorimetric Assay Kit enables rapid, quantitative detection of DEVD-dependent caspase-3 activity in apoptosis research and neurodegenerative disease studies. This kit is best suited for researchers requiring sensitive, workflow-compatible measurement of cysteine-dependent aspartate-directed protease activity, but should not be used for direct in vivo imaging or non-DEVD-targeted protease assays.

• COG133 Peptide Modulates miR-146a and Inflammation in Diabet

  2026-04-24

  This study investigates the ApoE-mimicked peptide COG133 for its ability to regulate miR-146a and reduce inflammatory signaling in diabetic dermal fibroblasts, alongside exhibiting antibacterial and antibiofilm properties. Findings highlight COG133’s potential in improving wound healing outcomes in diabetes by targeting molecular pathways implicated in chronic inflammation.

• Sabutoclax and the Future of Pan-Bcl-2 Inhibition in Oncolog

  2026-04-23

  This thought-leadership article explores the mechanistic underpinnings and translational promise of Sabutoclax, a potent pan-Bcl-2 inhibitor, in apoptosis-based cancer research. Bridging recent advances in drug response assessment and strategic considerations for translational workflows, it offers protocol guidance, competitive benchmarking, and a vision for the next generation of apoptosis-inducing therapeutics. Evidence from peer-reviewed studies and APExBIO’s validated product data is integrated throughout.

• Zolmitriptan (SKU B2261): Reliable 5-HT1B Agonist for Migrai

  2026-04-23

  This article delivers scenario-driven guidance for research teams using Zolmitriptan (SKU B2261), a potent and selective 5-HT1B receptor agonist. It addresses common laboratory challenges in cell-based assays, emphasizing experimental reliability, solubility, and data integrity. By referencing validated best practices and product specifications, this guide helps biomedical researchers optimize protocols and make evidence-based vendor choices.

• Clozapine N-oxide: Precision Tool for Neuronal Activity Modu

  2026-04-22

  Clozapine N-oxide (CNO) stands out as a gold-standard chemogenetic actuator for targeted neuronal activity modulation, enabling precise dissection of complex brain circuits. Its validated use in DREADDs-based workflows streamlines GPCR signaling research and empowers reproducible behavioral neuroscience assays.

15254 records 1/1017 page Next 12345 下5页 Last page